Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights from CANVAS.

Angel N BorisovAlexander KutzEmanuel R ChristMarkus H Heim Fahim Ebrahimi

Published in: The Journal of clinical endocrinology and metabolism (2023)

In patients with T2DM, treatment with canagliflozin vs. placebo resulted in improvements in liver biochemistry, metabolism, and might beneficially affect liver fibrosis.

Keyphrases

liver fibrosis
glycemic control
clinical trial
metabolic syndrome
adipose tissue
replacement therapy